Table 1.
Characteristics of the included literatures [no-reflow/reflow, n (%)]
| Author | Year | Country | Sample | Age | Males | Diabetes | Hypertension | Inflammatory factor |
|---|---|---|---|---|---|---|---|---|
| Celik [18] | 2016 | Turkey | 198 | 62±11 | 144 (72.7) | 72 (36.4) | 92 (46.5) | RDW/Neutrophil |
| 382 | 58±12 | 307 (80.4) | 89 (23.3) | 155 (40.6) | ||||
| Isik [19] | 2016 | Turkey | 30 | 64.5±12.4 | 23 (76.7) | 4 (13.3) | 13 (43.3) | |
| 66 | 58.9±12.3 | 51 (77.3) | 12 (18.2) | 20 (30.3) | ||||
| Wang [20] | 2016 | China | 43 | 65.3±12.7 | 31 (72.1) | 16 (37.2) | 27 (62.8) | Leukocyte/Neutrophil |
| 193 | 61.0±13.1 | 161 (83.4) | 59 (30.6) | 118 (61.1) | ||||
| Kurtul [21] | 2017 | Turkey | 194 | 67.1±13.4 | 122 (62.9) | 75 (38.7) | 84 (43.3) | |
| 1012 | 57.1±12.4 | 786 (77.7) | 275 (27.2) | 338 (33.4) | ||||
| Karabağ [22] | 2018 | Turkey | 343 | 59.0±12.8 | 272 (79.3) | 101 (29.4) | 155 (45.2) | |
| 874 | 56.0±11.6 | 720 (82.4) | 179 (20.5) | 336 (38.4) | ||||
| Tian [23] | 2017 | China | 56 | 56.1±11.7 | 50 (89.3) | 14 (25.0) | 30 (53.6) | |
| 305 | 55.0±11.8 | 269 (88.2) | 80 (26.2) | 165 (54.1) | ||||
| Sevket [24] | 2016 | Turkey | 199 | 62±12 | 145 (72.9) | 73 (36.7) | 92 (46.2) | |
| 401 | 58±12 | 325 (81.0) | 92 (22.9) | 158 (39.4) | ||||
| Orhan [25] | 2009 | Turkey | 137 | 60±12 | 103 (75) | 37 (27) | 55 (40) | |
| 206 | 57±11 | 165 (80) | 45 (22) | 76 (37) | ||||
| Huang [26] | 2016 | China | 28 | 56.8±13.0 | 21 (75) | 2 (7.1) | 7 (25.0) | |
| 115 | 58.0±11.0 | 92 (80) | 11 (9.6) | 31 (27.0) | ||||
| Ren [27] | 2016 | China | 19 | 63±10 | 12 (63.2) | 12 (63.2) | 14 (73.7) | |
| 64 | 57±10 | 46 (71.8) | 23 (35.9) | 42 (65.6) | ||||
| Sheng [28] | 2016 | China | 130 | 66.6±5.2 | 106 (81.5) | 38 (29.6) | 65 (50.0) | |
| 32 | 65.4±5.0 | 26 (81.3) | 10 (31.3) | 16 (50.0) | ||||
| Li [12] | 2018 | China | 38 | 65.6±11.2 | 20 (52.6) | 10 (26.3) | 19 (50.0) | Hs-CRP |
| 165 | 61.2±10.1 | 90 (54.5) | 40 (24.2) | 63 (38.2) | ||||
| Kuliczkowki [13] | 2015 | America | 27 | 61.0±7.2 | 18 (66.7) | -- | 20 (74) | |
| 33 | 62.8±5.4 | 21 (63.6) | -- | 25 (75) | ||||
| Hu [17] | 2022 | China | 32 | 63.0±11.7 | 23 (71.9) | 17 (53.1) | 14 (43.8) | |
| 44 | 54.9±9.00 | 33 (75.0) | 14 (43.8) | 14 (31.82) | ||||
| Su [29] | 2018 | China | 41 | 65.0±10.2 | 27 (68.3) | 18 (43.9) | 17 (41.5) | |
| 214 | 57.3±9.5 | 156 (72.9) | 67 (31.3) | 78 (36.4) | ||||
| Dogdu [30] | 2020 | Turkey | 35 | 64.0±11.8 | 28 (80.0) | 17 (48.6) | 14 (40.0) | |
| 45 | 66.8±11.5 | 32 (71.1) | 11 (24.4) | 16 (35.6) | ||||
| Zhao [31] | 2019 | China | 98 | 64.1±11.5 | 67 (68.4) | 37 (37.8) | 24 (24.5) | |
| 412 | 60.4±11.0 | 325 (78.9) | 113 (27.4) | 78 (18.9) | ||||
| Dong [38] | 2014 | China | 23 | 64.2±14.7 | -- | 11 (47.8) | 33 (42.9) | |
| 77 | 62.9±9.4 | -- | 30 (39.0) | 10 (43.5) | ||||
| ŞENÖZ [32] | 2021 | Turkey | 43 | 61.7±12.5 | 27 (62.8) | 20 (46.5) | 30 (69.7) | PLR/Neutrophil |
| 204 | 57.3±13.1 | 152 (74.5) | 53 (25.9) | 128 (62.7) | ||||
| Esenboga [33] | 2021 | Turkey | 110 | 62.1±12.7 | 77 (70.0) | 91 (82.7) | 57 (51.8) | |
| 400 | 62.0±11.5 | 314 (78.5) | 151 (37.8) | 237 (59.3) | ||||
| Kurtul [34] | 2015 | Turkey | 120 | 68.0±13.0 | 79 (65.8) | 43 (35.8) | 52 (43.3) | |
| 737 | 57.0±12.0 | 569 (77.2) | 198 (26.9) | 269 (36.5) | ||||
| Özmen [35] | 2021 | Turkey | 60 | 72.5±7.1 | 32 (53.3) | 19 (31.7) | 34 (56.7) | |
| 66 | 68.2±7.6 | 39 (59.1) | 32 (48.5) | 40 (60.7) | ||||
| Badran [36] | 2020 | Egypt | 58 | 52.9±11.1 | 49 (84.5) | 26 (44.8) | 31 (53.4) | |
| 142 | 111 (78.2) | 62 (43.7) | 71 (50.0) | |||||
| Wang [37] | 2018 | China | 43 | 65.3±12.7 | 31 (72.1) | 16 (37.2) | 27 (62.8) | Neutrophil |
| 193 | 61.0±13.1 | 161 (83.4) | 59 (30.6) | 118 (61.1) |